Using Genetics to Determine Disparities in Gastric Cancer

Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.

Ahead of the 2015 ASCO Annual Meeting, we are discussing over-the-counter therapies for patients with metastatic colorectal cancer with Andrew T. Chan, MD, MPH.

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.

Pembrolizumab plus lenvatinib showed a safety profile consistent with previous reports evaluating the combination.